Completed PHASE2/PHASE3 INTERVENTIONAL NCT00061776

NGX-4010 for the Treatment of Postherpetic Neuralgia

A Randomized, Double-Blind, Controlled Dose Finding Study of NGX-4010 for the Treatment of Postherpetic Neuralgia

Sponsor: NeurogesX

Conditions Herpes Zoster Neuralgia Pain Peripheral Nervous System Diseases Shingles

Updated 5 times since 2017 Last updated: Mar 4, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Herpes Zoster and Neuralgia and is currently completed. NeurogesX leads this study, which shows 5 recorded versions since 2026 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

NeurogesX

Data source: NeurogesX

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Austin, United States , Boston, United States , Dallas, United States , Denver, United States , Eugene, United States , Huntsville, United States , Kansas City, United States , La Jolla, United States , Las Vegas, United States and 18 more locations